Home
Science & Medicine
Diagnostic Oncology
Evolving Standards of Care
FDA Corner
Global Initiatives
Immunotherapy
Lung Cancer Screening
NCI Corner
Pathology
Prevention and Tobacco Control
Radiation Oncology
Supportive Care
Targeted Therapy
Advocacy & Survivorship
Thought-Leader Perspective
Allied Health
Meetings
Highlights
Preview
News
Breaking News Briefs
In Memoriam
People
Search
IASLC.org
IASLC Lung Cancer News
Home
Science & Medicine
Diagnostic Oncology
Evolving Standards of Care
FDA Corner
Global Initiatives
Immunotherapy
Lung Cancer Screening
NCI Corner
Pathology
Prevention and Tobacco Control
Radiation Oncology
Supportive Care
Targeted Therapy
Advocacy & Survivorship
Thought-Leader Perspective
Allied Health
Meetings
Highlights
Preview
News
Breaking News Briefs
In Memoriam
People
Home
Authors
Posts by lungcanc
lungcanc
526 POSTS
0 COMMENTS
Insight Into Genomic Correlates of PD-L1 Expression and the Response to...
lungcanc
Paul G. Kluetz, MD
lungcanc
cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib
lungcanc
PASSION Results Support Further Study of Camrelizumab Plus Apatinib in SCLC
lungcanc
Multidisciplinary Tumor Boards: Approaches Across Different Institutions
lungcanc
Shirish Gadgeel, MD
lungcanc
Prior Pneumonitis as a Risk Factor for Treatment-Associated Pneumonitis With Immune...
lungcanc
Karen L. Reckamp, MD, MS
lungcanc
Gideon Blumenthal, MD
lungcanc
David LeDuc
lungcanc
1
...
4
5
6
...
53
Page 5 of 53
Meeting News
Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation
Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation
TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse
cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib
Load more
Edit with Live CSS
